China Biologic Products, Inc. | TalkMarkets

Latest Posts

Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months

Article By: T.J. Hayes

Monday, September 9, 2019 7:36 PM EDT

The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.

In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB

Read

Week In Review: Three More China Biopharmas Planning Hong Kong IPOs

Article By: ChinaBio® Today

Saturday, August 25, 2018 4:14 PM EDT

Mabpharm Limited, a Taizhou biotech, will IPO in Hong Kong, the eleventh pre-revenue China biopharma to be approved to list there. Mabpharm is developing a portfolio of nine biosimilars, which it hopes will prove to be biobetters.

In this article: BNY, PFE, CBPO, BGNE, ZLAB

Read

Week In Review: CITIC Offers $3.6 Billion To Acquire China Biologic

Article By: ChinaBio® Today

Saturday, June 23, 2018 5:27 PM EDT

CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China's top five plasma-based biopharmas (. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding.

In this article: AZN, CBPO, PCRX, CSLLY, CASI

Read

Week In Review: Shanghai Pharma Bids In Cardinal China's $1.5 Billion Auction

Article By: ChinaBio® Today

Saturday, October 14, 2017 5:29 PM EDT

Shanghai Pharma (SHA: 601607) and FountainVest Partners, a China private equity fund, have submitted second-round bids for Cardinal China's (NYSE: CAH) drug distribution operations.

In this article: CAH, CASI, CBPO, BIIB

Read